Research Topics
Species | Elizabeth PhillipsSummaryAffiliation: Murdoch University Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Cytokine profiling in abacavir hypersensitivity patientsCoral Ann M Almeida
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Australia
Antivir Ther 13:281-8. 2008..We have analysed the cytokine profile in antigen-presenting cells and the T-lymphocytes that are involved in the pathological immune response to abacavir...- Drug hypersensitivity in HIVElizabeth Phillips
Centre for Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
Curr Opin Allergy Clin Immunol 7:324-30. 2007..This review focuses on the current knowledge of the epidemiology, pathophysiology and clinical features of drug hypersensitivity reactions of drugs used in the management of the HIV-infected patient... - Successful translation of pharmacogenetics into the clinic: the abacavir exampleElizabeth Phillips
Institute for Immunology and Infectious Diseases, Murdoch University and Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Western Australia, Australia
Mol Diagn Ther 13:1-9. 2009..The abacavir 'example' can be applied to other drugs to facilitate the development and operationalization of genetic tests that may be useful to predict and prevent otherwise unpredictable drug reactions... - External quality assessment of HLA-B*5701 reporting: an international multicentre surveyEmma Hammond
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
Antivir Ther 12:1027-32. 2007..We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR... - HLA-B*5701 screening for hypersensitivity to abacavirSimon Mallal
Royal Perth Hospital and Murdoch University, Perth, Australia
N Engl J Med 358:568-79. 2008..This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir... - Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variantAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Second Floor, North Block, Royal Perth Hospital, Perth 6000, Australia
Proc Natl Acad Sci U S A 101:4180-5. 2004..These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir... - High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patientsMichael Saag
Center for AIDS Research, University of Alabama at Birmingham, Birmingham, USA
Clin Infect Dis 46:1111-8. 2008..This study evaluated the sensitivity of detection of the HLA-B*5701 allele as a marker of ABC HSRs in both white and black patients, using skin patch testing to supplement clinical diagnosis... - Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' replyElizabeth Phillips
AIDS 22:548-9. 2008 - Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patientsElizabeth Phillips
British Columbia Centre for Excellence in HIV AIDS, Providence Healthcare, St Paul s Hospital, 667 1081 Burrard Street, Vancouver, BC, Canada
AIDS 21:1561-8. 2007.... - Immune responses to abacavir in antigen-presenting cells from hypersensitive patientsAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
AIDS 21:1233-44. 2007..HLA-B*5701 and Hsp70 493T alleles have been shown to predict susceptibility to this hypersensitivity... - A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndromeAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
Pharmacogenet Genomics 16:353-7. 2006..Following risk stratification with this assay, it would be anticipated that identification of HLA-B*5701 using molecular HLA typing methods would be required in <10% of the screened population... - Natural health product-HIV drug interactions: a systematic reviewEdward Mills
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON L8N 3Z5, Canada
Int J STD AIDS 16:181-6. 2005..Considering patient values and the implications of these studies, further research is urgently required to determine the extent of interactions with other commonly used NHPs... - Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell countsAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
AIDS 19:97-9. 2005..These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens... - Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapyMona Loutfy
Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
HIV Clin Trials 4:301-10. 2003..Although these factors were adjusted for in the multivariate analysis, a prospective randomized controlled trial is warranted to confirm our findings... - An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse drug events in an observational databaseJanet Raboud
Department of Medicine, University Health Network, University of Toronto, Ontario, Canada
HIV Clin Trials 8:311-9. 2007..This study was conducted to determine how frequently self-reported symptoms are captured as adverse drug events (ADEs) during chart abstraction... - Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistanceDavid Nolan
Clin Infect Dis 42:408-10. 2006 - Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicityAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
Pharmacogenomics 5:643-55. 2004..g., major histocompatibility complex alleles associated with abacavir hypersensitivity). The current and potential clinical utility of pharmacogenetic testing in HIV management will also be emphasized... - 'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effectsJohn R Sullivan
Division of Clinical Pharmacology, Sunnybrook and Woman's College Health Sciences Center, University of Toronto Medical School, Ontario, Canada
Contact Dermatitis 48:169-70. 2003